CalciMedica is trading 5.12% up in pre-market at $0.60 after Guggenheim initiated coverage with a Buy rating and a $9.00 price target on August 20, 2026.
- The analyst highlighted the pulmonary-hypertension pipeline, particularly CM5480 and Auxora.
- No newer company-specific announcement dated August 24, 2026 was identified.
- The gain appears to reflect continued investor reaction, although the stock remains below recent closes.